Shares of Brookdale Senior Living, Inc. (NYSE:BKD) ended Friday session in green amid volatile trading. The shares closed up +0.61 points or 3.62% at $17.60 with 2.10 million shares getting traded. Post opening the session at $17.05, the shares hit an intraday low of $16.94 and an intraday high of $17.62 and the price vacillated in this range throughout the day. The company has a market cap of $3.23 billion and the numbers of outstanding shares have been calculated to be 185.91 million shares.
Brookdale Senior Living, Inc. (BKD) announced that management will participate in a discussion regarding the Company at the Wells Fargo 2016 Healthcare Conference in Boston, Massachusetts on Thursday, September 8, 2016, beginning at 2:20 p.m. Eastern Time.
The presentation is being audio webcast live and can be accessed on the Internet at https://cc.talkpoint.com/well001/090716a_ae/?entity=85_WFB86BL as well as through the Investor Relations section of the Company’s website at brookdale.com. A replay of the webcast will be available for 90 days after the discussion.
Shares of Sanofi SA (ADR) (NYSE:SNY) ended Friday session in green amid volatile trading. The shares closed up +0.77 points or 2.00% at $39.18 with 1.31 million shares getting traded. Post opening the session at $39.27, the shares hit an intraday low of $39.02 and an intraday high of $39.30 and the price vacillated in this range throughout the day. The company has a market cap of $100.13 billion and the numbers of outstanding shares have been calculated to be 1.29 billion shares.
On Aug. 13, 2016 Sanofi and its vaccines global business unit Sanofi Pasteur announced that 500,000 doses of Dengvaxia® have been received in Parana to support a large-scale public dengue immunization program initiated in the State’s 30 most highly endemic municipalities.
Parana State, home to 10 million people, has seen a steep 3-fold increase in both dengue incidence and deaths in recent years. In the last year, there have been 55,000 cases reported, costing the State an estimated R$ 330 million (~91 M Euro) in related healthcare expenses.
“For the public immunization program being launched, we have used our extensive dengue surveillance data to ensure that we are targeting people at highest risk of disease. We will vaccinate all individuals 15-27 years of age in 28 municipalities and 9-44 years of age in the two municipalities with the top dengue burden in our State over the next three weeks,” said Michele Caputo Neto, Parana Health Secretary.
“Parana has a good track record in vaccination coverage in general and successful implementation of this dengue immunization strategy could result in 74% reduction in disease burden in these highly impacted municipalities within 5 years, according to a dengue vaccine impact study published in the Brazilian Journal of Health Economics,” Secretary Neto noted.
Dr. Stephen J. Thomas, a physician-scientist at the Walter Reed Army Institute of Research in Silver Spring, Maryland who is an international dengue expert commented on the public immunization program initiated by Parana State. “Dengue remains one of the world’s most important mosquito transmitted diseases causing significant human suffering and financial cost. The strategic deployment of a safe and effective dengue vaccine offers the best hope of reducing dengue’s burden, especially in highly endemic countries like Brazil.”